- Home
- PZG vs PRLD Comparison
PZG vs PRLD Comparison
Compare PZG & PRLD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PZG
- PRLD
- Stock Information
- Founded
- PZG 1992
- PRLD 2016
- Country
- PZG United States
- PRLD United States
- Employees
- PZG N/A
- PRLD N/A
- Industry
- PZG Metal Mining
- PRLD Medicinal Chemicals and Botanical Products
- Sector
- PZG Basic Materials
- PRLD Health Care
- Exchange
- PZG Nasdaq
- PRLD Nasdaq
- Market Cap
- PZG 48.4M
- PRLD 44.0M
- IPO Year
- PZG 1999
- PRLD 2020
- Fundamental
- Price
- PZG $0.84
- PRLD $1.24
- Analyst Decision
- PZG
- PRLD Strong Buy
- Analyst Count
- PZG 0
- PRLD 3
- Target Price
- PZG N/A
- PRLD $4.00
- AVG Volume (30 Days)
- PZG 477.2K
- PRLD 186.5K
- Earning Date
- PZG 09-25-2025
- PRLD 08-14-2025
- Dividend Yield
- PZG N/A
- PRLD N/A
- EPS Growth
- PZG N/A
- PRLD N/A
- EPS
- PZG N/A
- PRLD N/A
- Revenue
- PZG N/A
- PRLD $7,000,000.00
- Revenue This Year
- PZG N/A
- PRLD N/A
- Revenue Next Year
- PZG N/A
- PRLD N/A
- P/E Ratio
- PZG N/A
- PRLD N/A
- Revenue Growth
- PZG N/A
- PRLD N/A
- 52 Week Low
- PZG $0.31
- PRLD $0.61
- 52 Week High
- PZG $0.87
- PRLD $5.95
- Technical
- Relative Strength Index (RSI)
- PZG 72.21
- PRLD 74.20
- Support Level
- PZG $0.73
- PRLD $0.85
- Resistance Level
- PZG $0.85
- PRLD $0.96
- Average True Range (ATR)
- PZG 0.04
- PRLD 0.11
- MACD
- PZG 0.02
- PRLD 0.04
- Stochastic Oscillator
- PZG 87.12
- PRLD 98.00
About PZG Paramount Gold Nevada Corp.
Paramount Gold Nevada Corp is an exploration-stage mining company. Together with its subsidiaries, the company is engaged in the business of acquiring, exploring, and developing precious metal projects in the United States. Also, it explores for gold and silver. The company enhances the value of projects by implementing exploration and engineering programs that are likely to expand and upgrade known mineralized material to reserves. Its projects include sleeper gold, grassy mountain gold, frost project, other non-material, and others.
About PRLD Prelude Therapeutics Incorporated
Prelude Therapeutics Incorp is a clinical stage precision oncology company focused on discovering and developing small molecule therapies optimized to target the key driver mechanisms in cancers with high unmet needs. The company's pipeline includes four candidates currently in clinical development: PRT1419, a potent, selective inhibitor of MCL1; PRT2527, a potent and selective CDK9 inhibitor, PRT3645, a next-generation CDK4/6 inhibitor, and PRT3789 a first-in-class SMARCA2/BRM protein degrader.